Hoechst Refocuses Following Restructuring

12 December 1994

Hoechst's European industrial business is forecast to move out of the red this year, although the figures will still be a long way from an acceptable return on equity, said Jurgen Dormann, chairman of the board at Hoechst AG, speaking at the firm's Fall meeting (see also Marketletter December 5).

Mr Dormann specified that the board has set a target for net return of about 15%, compared with its current rate of around 4.6%. With this in mind, said Mr Dormann, it is expected that the profit fall of 2 billion Deutschemarks ($1.3 billion) will be turned around by 1996. In addition, he noted, substantial cost savings should result from the huge restructuring program. Cost savings for 1995 alone are expected to reach 250 million marks.

Continuing on his theme of restructuring, Mr Dormann said that in view of the dimensions involved, conventional measures no longer suffice. It is vital that the group improves its competitive position by streamlining the organization, by spinning off businesses and by cooperative ventures with partners. Through spin-offs and joint ventures there will be a provision for individual activities within the company framework to enable these businesses to become more flexible and competitive in their specific markets, he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight